[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351590-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351590-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","artesunate-induces-g0g1-phase-arrest-in-tumor-cells-and-associates-with-cyclin-dependent-kinase-4-cdk4","Artesunate Induces G0/G1 Phase Arrest in Tumor Cells and Associates With Cyclin-Dependent Kinase 4 (CDK4)","","Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality, and CDK4 is a validated oncogenic driver, yet current aminopyrimidine CDK4 inhibitors face structural limitations and rapid acquired resistance. This study uses a HuProt human proteome microarray to identify direct cellular targets of artesunate, an FDA-approved artemisinin derivative. Docking, SPR, and kinase assays show direct CDK4 binding, strong biochemical inhibition, and artesunate-driven G0/G1 arrest via the CDK4–Rb–E2F axis in NSCLC models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/artesunate-induces-g0g1-phase-arrest-in-tumor-cells-and-associates-with-cyclin-dependent-kinase-4-cdk4/351590/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/artesunate-induces-g0g1-phase-arrest-in-tumor-cells-and-associates-with-cyclin-dependent-kinase-4-cdk4/351590.png","ImageObject",300,407,{"name":42,"@type":43},"Chumphorn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of this research on artesunate and CDK4?","Question",{"text":63,"@type":64},"To determine whether artesunate directly targets CDK4 and to evaluate how that interaction affects cell-cycle progression in NSCLC models.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study confirm that artesunate binds to CDK4?",{"text":68,"@type":64},"HuProt proteome microarray screening identified CDK4, and the binding was validated using molecular docking, surface plasmon resonance (SPR), and in vitro kinase assays.",{"name":70,"@type":61,"acceptedAnswer":71},"What cellular effect did artesunate produce in NSCLC cells?",{"text":72,"@type":64},"Artesunate induced significant G0/G1 phase cell-cycle arrest in A549 and H1299 cells, mediated by inhibition of the CDK4–Rb–E2F axis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351590,1790206912,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":118,"preview_page_count":33,"preview_urls":144},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nArtesunate Induces G0/G1 Phase Arrest in Tumor Cells and Associates With Cyclin-Dependent Kinase 4 (CDK4)  \nXinyu Chi1 | Qicong Chen2 | Gang Wang2 | Honglin Luo2 | Shenhong Qu2 | Xiaosu Zou2  \n1Research Center of Communicable and Severe Diseases, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China | 2Institute of Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China  \nCorrespondence: Shenhong Qu ([shqu@gxams.org.cn](shqu@gxams.org.cn)) | Xiaosu Zou ([zxs_tcm@163.com](zxs_tcm@163.com))  \nReceived: 1 December 2025 | Revised: 7 April 2026 | Accepted: 23 April 2026  \nKeywords: artesunate | CDK4 | cell cycle arrest | human proteome microarray | lung cancer  \nABSTRACT  \nBackground: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. Cyclin-dependent kinase 4 (CDK4) is a well-validated oncogenic driver in NSCLC, yet current CDK4 inhibitors—predominantly based on the aminopyrimidine scaffold—are limited by structural homogeneity and the rapid emergence of acquired resistance, underscoring the need for novel chemotypes.  \nMethods: We employed a HuProt human proteome microarray to screen for direct cellular targets of artesunate, an FDA-approved artemisinin derivative. Candidate interactions were validated by molecular docking, surface plasmon resonance (SPR), and in vitro kinase assays. Functional effects were assessed in A549 and H1299 NSCLC cell lines using flow cytometry and Western blotting. Results: Artesunate was identified as a direct binder of CDK4, with molecular docking revealing a strong binding affinity (−7.069kcal/mol). SPR analysis confirmed this interaction with a Kd of 488 μM, and in vitro kinase assays demonstrated potent inhibition of CDK4/Cyclin D3 activity (IC50 = 0.2943 μM) . Treatment with artesunate induced significant G0/G1 cell cycle arrest in both A549 and H1299 cells. This effect was mediated through inhibition of the CDK4–Rb–E2F axis, as evidenced by dosedependent suppression of Rb phosphorylation at Ser780 and Ser795 .  \nConclusion: Our findings establish artesunate as a structurally distinct, non-aminopyrimidine CDK4 inhibitor with potent biochemical and cellular activity in NSCLC models. This work provides a promising therapeutic strategy to circumvent resistance associated with current CDK4 inhibitors and supports the repurposing of artesunate for CDK4-driven cancers.  \n1 | Introduction  \nLung cancer remains the leading cause of cancer-related mortality worldwide, accounting for approximately 20% of all cancer deaths, with a dismal 5-year overall survival rate of 17.8%  \n[1]. Non-small cell lung cancer (NSCLC) constitutes 80%–85% of lung cancer cases. CDK4/6 drives cell cycle progression via RB phosphorylation and shows broad therapeutic potential owing to its dual role in NSCLC and SCLC [2, 3] . The CDK4/6–Rb– E2F pathway is hyperactivated in > 68% of adenocarcinoma cases [4, 5] . The conserved role of CDK4/6 in cell cycle control across lung cancer subtypes supports its therapeutic relevance  \nin NSCLC. Recent clinical evidence has demonstrated that CDK4/6 inhibitors significantly increase the efficacy of chemotherapy in treating lung cancer by reversing T-cell exhaustion and promoting antitumor immunity [6] . CDK4 plays a critical cancer-driving role in NSCLC, making the development of effective targeted therapeutics against this protein a major research focus in NSCLC treatment.  \nArtemisinin derivatives offer structurally distinct alternatives assesquiterpene lactones containing unique endoperoxide bridges. Numerous studies have shown that these compounds have excellent antitumor effects and should thus be a focus of research [7–9].  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-com","cbCaidu1AuYPLEB3","https://ap.wps.com/l/cbCaidu1AuYPLEB3","pdf",2227014,"English","# Introduction\n# Results\n## The Artesunate–Biotin Probe Retained the Ability to Inhibit Cell Proliferation","[{\"question\":\"What was the main goal of this research on artesunate and CDK4?\",\"answer\":\"To determine whether artesunate directly targets CDK4 and to evaluate how that interaction affects cell-cycle progression in NSCLC models.\"},{\"question\":\"How did the study confirm that artesunate binds to CDK4?\",\"answer\":\"HuProt proteome microarray screening identified CDK4, and the binding was validated using molecular docking, surface plasmon resonance (SPR), and in vitro kinase assays.\"},{\"question\":\"What cellular effect did artesunate produce in NSCLC cells?\",\"answer\":\"Artesunate induced significant G0/G1 phase cell-cycle arrest in A549 and H1299 cells, mediated by inhibition of the CDK4–Rb–E2F axis.\"}]","Artesunate Induces G0/G1 Phase Arrest in Tumor Cells and Associates With Cyclin-Dependent Kinase 4 (CDK4) | PDF",1790094863,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef3f731f873c34ffef78ce6ac637de42.webp",983,1291,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a27790105fa41f43179911746ca2359.webp",982,1290,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/889279faa8ac1ff6fa8df912301c37bd.webp",981,1289,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85ae847b4ec2027ec4ec7c3e66d54a57.webp",980,1287]